Results 81 to 90 of about 26,327 (353)

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundOur aim was to evaluate the association between the soluble form of neprilysin (sNEP) levels and long‐term all‐cause, cardiovascular, and acute heart failure (AHF) recurrent admissions in an ambulatory cohort of patients with heart failure ...
Julio Núñez, Eduardo Núñez, Jaume Barallat, Vicent Bodí, Gema Miñana, M. Cruz Pastor, Juan Sanchis, Josep Lupón, Antoni Bayes‐Genis   +8 more
doaj   +1 more source

Sacubitril/valsartan:beyond natriuretic peptides [PDF]

, 2017
Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily been regarded as biomarkers in heart failure (HF). However, they are also possible therapeutic agents due to potentially beneficial physiological effects.
Atlas, Bateman, Cannon, Carpentier, Cohn, Daniels, Dehlin, Dell’Italia, Emdin, Fan, Gainer, Graf, Hirata, Hubers, Ibebuogu, Kalra, Kon, Laine, Langenickel, Liang, Maack, McMurray, McMurray, McMurray, Meilandt, Miller, Mione, Mistry, Nagaya, Niederkofler, Ohno-Matsui, Okolicany, Packer, Parthasarathy, Pelc, Potter, Potter, Rechardt, Richards, Richards, Singh, Tom, Tsutamoto, Vardeny, Vodovar, Witherow, Wong, Yasojima, Zile   +48 more
core   +2 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?

Biology, 2022
Myocardial wall stress, cytokines, hormones, and ischemia all stimulate B-type (or brain) natriuretic peptide (BNP) gene expression. Within the myocardium, ProBNP-108, a BNP precursor, undergoes glycosylation, after which a portion is cleaved by furin ...
Toshio Nishikimi, Yasuaki Nakagawa
doaj   +1 more source

N‐terminal pro‐brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi, Masaomi Nangaku, Tadashi Sofue, Tatsuo Kagimura, Ichiei Narita   +4 more
wiley   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki, Tetsu Watanabe, Mari Shimizu, Shingo Tachibana, Junya Sato, Yuta Kobayashi, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source

Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications

Frontiers in Pharmacology
Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system.
Xinyue Zhang, Chun Hu, Erkang Tian, Yanxin Shen, Wei Liu, Juan Li   +5 more
doaj   +1 more source

The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction

Cells, 2020
During the last three decades, timely myocardial reperfusion using either thrombolytic therapy or primary percutaneous intervention (pPCI) has allowed amazing improvements in outcomes with a more than halving in 1-year ST-elevation myocardial infarction (
Alessandro Bellis, Ciro Mauro, Emanuele Barbato, Giuseppe Di Gioia, Daniela Sorriento, Bruno Trimarco, Carmine Morisco   +6 more
doaj   +1 more source